A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC).
2011 ◽
Vol 29
(15_suppl)
◽
pp. 3044-3044
◽
Keyword(s):